WO2002024647A1 - Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine - Google Patents
Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine Download PDFInfo
- Publication number
- WO2002024647A1 WO2002024647A1 PCT/JP2001/008176 JP0108176W WO0224647A1 WO 2002024647 A1 WO2002024647 A1 WO 2002024647A1 JP 0108176 W JP0108176 W JP 0108176W WO 0224647 A1 WO0224647 A1 WO 0224647A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- syndrome
- active ingredient
- diseases
- receptor agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001290250A AU2001290250A1 (en) | 2000-09-21 | 2001-09-20 | Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-286696 | 2000-09-21 | ||
JP2000286696 | 2000-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002024647A1 true WO2002024647A1 (fr) | 2002-03-28 |
Family
ID=18770579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/008176 WO2002024647A1 (fr) | 2000-09-21 | 2001-09-20 | Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001290250A1 (fr) |
WO (1) | WO2002024647A1 (fr) |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003074483A1 (fr) * | 2002-03-05 | 2003-09-12 | Ono Pharmaceutical Co., Ltd. | Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif |
WO2003077910A1 (fr) * | 2002-03-18 | 2003-09-25 | Pfizer Products Inc. | Procedes de traitement au moyen d'agonistes selectifs du recepteur ep4 |
WO2003103772A1 (fr) * | 2002-06-06 | 2003-12-18 | Merck Frosst Canada & Co. | Derives de pyrrolid-2-one 1,5 disubstitues utilises comme agonistes de recepteur ep4 pour traiter des maladies oculaires telles que le glaucome |
WO2003103664A1 (fr) * | 2002-06-06 | 2003-12-18 | Merck Frosst Canada & Co. | Derives d'imidazolidine-2-one disubstitues en 1,5 utiles en tant qu'agonistes du recepteur ep4 dans le traitement de troubles oculaires et de maladies osseuses |
US6734206B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
US6734201B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents |
WO2004037786A3 (fr) * | 2002-10-25 | 2004-09-30 | Merck Frosst Canada Inc | Agonistes des recepteurs ep4 |
US6849657B2 (en) | 2001-07-16 | 2005-02-01 | Syntex (U.S.A.) Llc | 2-pyrrolidone derivatives as prostanoid agonists |
US6900336B2 (en) | 2001-07-16 | 2005-05-31 | Syntex (U.S.A.) Llc | 8-aza-11-deoxy prostaglandin analogues |
US6906097B2 (en) | 2002-05-14 | 2005-06-14 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
EP1586564A1 (fr) * | 2003-01-21 | 2005-10-19 | Ono Pharmaceutical Co., Ltd. | Derives de 8-azaprostalangine et utilisations de ces derives en tant que medicaments |
US7053085B2 (en) | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
WO2007017687A2 (fr) | 2005-08-09 | 2007-02-15 | Asterand Uk Limited | Agonistes des recepteurs ep2 |
US7196082B2 (en) | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
WO2007064664A2 (fr) * | 2005-11-30 | 2007-06-07 | Allergan, Inc. | Procedes therapeutiques mettant en oeuvre des composants agonistes ep4 de prostaglandine |
US7276531B2 (en) | 2003-03-03 | 2007-10-02 | Applied Research Systems Ars Holding N.V. | G-lactam derivatives as prostaglandin agonists |
US7326732B2 (en) | 2004-02-12 | 2008-02-05 | Pharmagene Laboratories Limited | EP2 receptor agonists |
US7410992B2 (en) | 2003-09-04 | 2008-08-12 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
US7419999B2 (en) | 2002-06-10 | 2008-09-02 | Applied Research Systems Ars Holding N.V. | Gamma lactams as prostaglandin agonists and use thereof |
US7465755B2 (en) | 2003-07-18 | 2008-12-16 | Laboratoires Serono Sa | Hydrazide derivatives as prostaglandin receptors modulators |
US7494983B2 (en) | 2003-09-04 | 2009-02-24 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
US7528163B2 (en) | 2002-11-08 | 2009-05-05 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
US7531533B2 (en) | 2005-01-27 | 2009-05-12 | Asahi Kasei Pharma Corporation | 6-Membered heterocyclic compound and use thereof |
US7563816B2 (en) | 2004-07-20 | 2009-07-21 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
US7576122B2 (en) | 2003-09-02 | 2009-08-18 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
US7608637B2 (en) | 2001-07-23 | 2009-10-27 | Ono Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient |
JP2010047580A (ja) * | 2003-01-10 | 2010-03-04 | F Hoffmann La Roche Ag | プロスタグランジンアゴニストとしての2−ピペリドン誘導体 |
US7696243B2 (en) | 2004-12-06 | 2010-04-13 | Merck Serono, S.A. | Pyrrolidin-2-one derivatives for use as DP1 receptor agonists |
WO2010113957A1 (fr) | 2009-03-30 | 2010-10-07 | 宇部興産株式会社 | Composition pharmaceutique pour la prévention ou le traitement du glaucome |
CN101133037B (zh) * | 2005-01-27 | 2012-05-09 | 旭化成制药株式会社 | 六元杂环化合物及其用途 |
US8648097B2 (en) | 2008-03-12 | 2014-02-11 | Ube Industries, Ltd. | Pyridylaminoacetic acid compound |
US9180116B2 (en) | 2012-07-19 | 2015-11-10 | Cayman Chemical Company, Inc. | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
US9394520B2 (en) | 2006-12-08 | 2016-07-19 | University Of Rochester | Expansion of hematopoietic stem cells |
WO2016199111A1 (fr) | 2015-06-12 | 2016-12-15 | Simon Fraser University | Composés agoniste d'ep4-bisphosphonate à liaison amide et leurs utilisations |
US9611284B2 (en) | 2010-05-28 | 2017-04-04 | Simon Fraser University | Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof |
US9650414B1 (en) | 2014-05-30 | 2017-05-16 | Simon Fraser University | Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof |
US9676712B2 (en) | 2013-03-15 | 2017-06-13 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
US9688627B2 (en) | 2013-03-15 | 2017-06-27 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
WO2019131582A1 (fr) | 2017-12-25 | 2019-07-04 | 旭化成ファーマ株式会社 | Composé cyclique à six chaînons contenant de l'azote |
US10729810B2 (en) | 2013-07-19 | 2020-08-04 | Cayman Chemical Company, Inc | Methods, systems, and compositions for promoting bone growth |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS525764A (en) * | 1975-06-27 | 1977-01-17 | Hoechst Ag | Production of pyrrolidone |
JPS52133975A (en) * | 1976-05-04 | 1977-11-09 | Hoechst Ag | Pyrrolidones and their preparation |
JPS5321159A (en) * | 1976-08-06 | 1978-02-27 | Pfizer | 1*55disubstitutedd22pyrrolidones |
JPS5754166A (en) * | 1980-08-11 | 1982-03-31 | Du Pont | 88azaa16 166jifuruorupurosutanoido |
JPH10265454A (ja) * | 1997-01-27 | 1998-10-06 | Ono Pharmaceut Co Ltd | 3,7−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 |
JP2001233792A (ja) * | 2000-01-31 | 2001-08-28 | Pfizer Prod Inc | 急性及び慢性腎不全の処置のためのプロスタグランジン(pge2)受容体4(ep4)選択的アゴニストの使用 |
-
2001
- 2001-09-20 WO PCT/JP2001/008176 patent/WO2002024647A1/fr active Application Filing
- 2001-09-20 AU AU2001290250A patent/AU2001290250A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS525764A (en) * | 1975-06-27 | 1977-01-17 | Hoechst Ag | Production of pyrrolidone |
JPS52133975A (en) * | 1976-05-04 | 1977-11-09 | Hoechst Ag | Pyrrolidones and their preparation |
JPS5321159A (en) * | 1976-08-06 | 1978-02-27 | Pfizer | 1*55disubstitutedd22pyrrolidones |
JPS5754166A (en) * | 1980-08-11 | 1982-03-31 | Du Pont | 88azaa16 166jifuruorupurosutanoido |
JPH10265454A (ja) * | 1997-01-27 | 1998-10-06 | Ono Pharmaceut Co Ltd | 3,7−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 |
JP2001233792A (ja) * | 2000-01-31 | 2001-08-28 | Pfizer Prod Inc | 急性及び慢性腎不全の処置のためのプロスタグランジン(pge2)受容体4(ep4)選択的アゴニストの使用 |
Cited By (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6900336B2 (en) | 2001-07-16 | 2005-05-31 | Syntex (U.S.A.) Llc | 8-aza-11-deoxy prostaglandin analogues |
US6849657B2 (en) | 2001-07-16 | 2005-02-01 | Syntex (U.S.A.) Llc | 2-pyrrolidone derivatives as prostanoid agonists |
US8207223B2 (en) | 2001-07-23 | 2012-06-26 | Ono Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient |
US7608637B2 (en) | 2001-07-23 | 2009-10-27 | Ono Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient |
JP2012111767A (ja) * | 2001-07-23 | 2012-06-14 | Ono Pharmaceut Co Ltd | Ep4アゴニストを有効成分とする骨量低下疾患の治療剤 |
WO2003074483A1 (fr) * | 2002-03-05 | 2003-09-12 | Ono Pharmaceutical Co., Ltd. | Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif |
US8026273B2 (en) | 2002-03-05 | 2011-09-27 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient |
US7402605B2 (en) | 2002-03-05 | 2008-07-22 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient |
US7683094B2 (en) | 2002-03-05 | 2010-03-23 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient |
WO2003077910A1 (fr) * | 2002-03-18 | 2003-09-25 | Pfizer Products Inc. | Procedes de traitement au moyen d'agonistes selectifs du recepteur ep4 |
JP2005530796A (ja) * | 2002-05-14 | 2005-10-13 | アラーガン、インコーポレイテッド | 眼圧降下剤としての8−アザプロスタグランジン類似体 |
US6906097B2 (en) | 2002-05-14 | 2005-06-14 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
JP2011116768A (ja) * | 2002-05-14 | 2011-06-16 | Allergan Inc | 眼圧降下剤としての8−アザプロスタグランジン類似体 |
US20130317013A1 (en) * | 2002-06-06 | 2013-11-28 | Xavier Billot | Ep4 receptor agonist, compositions and methods thereof |
JP2005537235A (ja) * | 2002-06-06 | 2005-12-08 | メルク フロスト カナダ アンド カンパニー | Ep4受容体作動薬、組成物及びその方法 |
JP4766875B2 (ja) * | 2002-06-06 | 2011-09-07 | メルク フロスト カナダ リミテツド | Ep4受容体作動薬、組成物及びその方法 |
WO2003103664A1 (fr) * | 2002-06-06 | 2003-12-18 | Merck Frosst Canada & Co. | Derives d'imidazolidine-2-one disubstitues en 1,5 utiles en tant qu'agonistes du recepteur ep4 dans le traitement de troubles oculaires et de maladies osseuses |
WO2003103772A1 (fr) * | 2002-06-06 | 2003-12-18 | Merck Frosst Canada & Co. | Derives de pyrrolid-2-one 1,5 disubstitues utilises comme agonistes de recepteur ep4 pour traiter des maladies oculaires telles que le glaucome |
US7419999B2 (en) | 2002-06-10 | 2008-09-02 | Applied Research Systems Ars Holding N.V. | Gamma lactams as prostaglandin agonists and use thereof |
WO2004037786A3 (fr) * | 2002-10-25 | 2004-09-30 | Merck Frosst Canada Inc | Agonistes des recepteurs ep4 |
US7196082B2 (en) | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
US7547720B2 (en) | 2002-11-08 | 2009-06-16 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
US7528163B2 (en) | 2002-11-08 | 2009-05-05 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
US7238710B2 (en) | 2002-12-04 | 2007-07-03 | Merck Frosst Canada, Ltd. | EP4 receptor agonist, compositions and methods thereof |
JP2010047580A (ja) * | 2003-01-10 | 2010-03-04 | F Hoffmann La Roche Ag | プロスタグランジンアゴニストとしての2−ピペリドン誘導体 |
EP1586564A4 (fr) * | 2003-01-21 | 2008-04-30 | Ono Pharmaceutical Co | Derives de 8-azaprostalangine et utilisations de ces derives en tant que medicaments |
EP1586564A1 (fr) * | 2003-01-21 | 2005-10-19 | Ono Pharmaceutical Co., Ltd. | Derives de 8-azaprostalangine et utilisations de ces derives en tant que medicaments |
US7276531B2 (en) | 2003-03-03 | 2007-10-02 | Applied Research Systems Ars Holding N.V. | G-lactam derivatives as prostaglandin agonists |
USRE42562E1 (en) | 2003-03-26 | 2011-07-19 | Merck Frosst Canada | EP4 receptor agonist, compositions and methods thereof |
US7053085B2 (en) | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
US6812240B1 (en) | 2003-06-02 | 2004-11-02 | Allergan, Inc. | 8-azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents |
US6734206B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
US6734201B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents |
US7005442B2 (en) | 2003-06-02 | 2006-02-28 | Allergan, Inc. | 8-azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents |
WO2004108670A1 (fr) | 2003-06-02 | 2004-12-16 | Allergan, Inc. | Analogues de 3-oxa-8-azaprostaglandine utilises en tant qu'agents de reduction de la pression intraoculiare |
US7465755B2 (en) | 2003-07-18 | 2008-12-16 | Laboratoires Serono Sa | Hydrazide derivatives as prostaglandin receptors modulators |
US7576122B2 (en) | 2003-09-02 | 2009-08-18 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
US7494983B2 (en) | 2003-09-04 | 2009-02-24 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
US7410992B2 (en) | 2003-09-04 | 2008-08-12 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
US7662839B2 (en) | 2004-02-12 | 2010-02-16 | Asterand Uk Limited | EP2 receptor agonists |
US7803841B2 (en) | 2004-02-12 | 2010-09-28 | Asterand Uk Limited | EP2 receptor agonists |
US7326732B2 (en) | 2004-02-12 | 2008-02-05 | Pharmagene Laboratories Limited | EP2 receptor agonists |
US7563816B2 (en) | 2004-07-20 | 2009-07-21 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
US7696243B2 (en) | 2004-12-06 | 2010-04-13 | Merck Serono, S.A. | Pyrrolidin-2-one derivatives for use as DP1 receptor agonists |
CN101133037B (zh) * | 2005-01-27 | 2012-05-09 | 旭化成制药株式会社 | 六元杂环化合物及其用途 |
US7531533B2 (en) | 2005-01-27 | 2009-05-12 | Asahi Kasei Pharma Corporation | 6-Membered heterocyclic compound and use thereof |
WO2007017687A2 (fr) | 2005-08-09 | 2007-02-15 | Asterand Uk Limited | Agonistes des recepteurs ep2 |
US8080567B2 (en) | 2005-08-09 | 2011-12-20 | Asterand Uk Limited | EP2 receptor agonists |
US7893107B2 (en) | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
WO2007064664A3 (fr) * | 2005-11-30 | 2007-07-19 | Allergan Inc | Procedes therapeutiques mettant en oeuvre des composants agonistes ep4 de prostaglandine |
WO2007064664A2 (fr) * | 2005-11-30 | 2007-06-07 | Allergan, Inc. | Procedes therapeutiques mettant en oeuvre des composants agonistes ep4 de prostaglandine |
US9394520B2 (en) | 2006-12-08 | 2016-07-19 | University Of Rochester | Expansion of hematopoietic stem cells |
US8648097B2 (en) | 2008-03-12 | 2014-02-11 | Ube Industries, Ltd. | Pyridylaminoacetic acid compound |
WO2010113957A1 (fr) | 2009-03-30 | 2010-10-07 | 宇部興産株式会社 | Composition pharmaceutique pour la prévention ou le traitement du glaucome |
US8685986B2 (en) | 2009-03-30 | 2014-04-01 | Ube Industries, Ltd. | Medical composition for treatment or prophylaxis of glaucoma |
US9611284B2 (en) | 2010-05-28 | 2017-04-04 | Simon Fraser University | Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof |
US11066361B2 (en) | 2012-07-19 | 2021-07-20 | Cayman Chemical Company, Inc. | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
US9487478B2 (en) | 2012-07-19 | 2016-11-08 | Cayman Chemical Company, Inc. | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
US11884624B2 (en) | 2012-07-19 | 2024-01-30 | Cayman Chemical Company, Inc. | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
US9180116B2 (en) | 2012-07-19 | 2015-11-10 | Cayman Chemical Company, Inc. | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
US9440919B2 (en) | 2012-07-19 | 2016-09-13 | Cayman Chemical Company, Inc. | Difluorolactam compositions for EP4-mediated osteo related diseases and conditions |
US9701630B2 (en) | 2012-07-19 | 2017-07-11 | Cayman Chemical Company, Inc. | Difluorolactam compositions for EP4-mediated osteo related diseases and conditions |
US9688627B2 (en) | 2013-03-15 | 2017-06-27 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
US9676712B2 (en) | 2013-03-15 | 2017-06-13 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
US10729810B2 (en) | 2013-07-19 | 2020-08-04 | Cayman Chemical Company, Inc | Methods, systems, and compositions for promoting bone growth |
US9650414B1 (en) | 2014-05-30 | 2017-05-16 | Simon Fraser University | Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof |
US10400000B2 (en) | 2015-06-12 | 2019-09-03 | Simon Fraser University | Amide-linked EP4 agonist-bisphosphonate compounds and uses thereof |
WO2016199111A1 (fr) | 2015-06-12 | 2016-12-15 | Simon Fraser University | Composés agoniste d'ep4-bisphosphonate à liaison amide et leurs utilisations |
US11312737B2 (en) | 2015-06-12 | 2022-04-26 | Simon Fraser University | Amide-linked EP4 agonist-bisphosphonate compounds and uses thereof |
WO2019131582A1 (fr) | 2017-12-25 | 2019-07-04 | 旭化成ファーマ株式会社 | Composé cyclique à six chaînons contenant de l'azote |
US10988468B2 (en) | 2017-12-25 | 2021-04-27 | Asahi Kasei Pharma Corporation | Nitrogen-containing 6-membered cyclic compound |
US11667630B2 (en) | 2017-12-25 | 2023-06-06 | Asahi Kasei Pharma Corporation | Nitrogen-containing 6-membered cyclic compound |
KR20200073265A (ko) | 2017-12-25 | 2020-06-23 | 아사히 가세이 파마 가부시키가이샤 | 함질소 6원환 화합물 |
Also Published As
Publication number | Publication date |
---|---|
AU2001290250A1 (en) | 2002-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002024647A1 (fr) | Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine | |
WO2003074483A1 (fr) | Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif | |
WO2000058293A3 (fr) | Activateurs de glucokinase | |
HK1074588A1 (en) | Aqueous suspension comprising fenofibrate | |
WO2002068227A8 (fr) | Suspension de vehicule | |
DK1200521T3 (da) | Dispersion med ikke-ionisk emulgator | |
WO2005085234A3 (fr) | Nouveaux insecticides | |
GB2367239C (en) | Folding frame construction | |
CN101528082A (zh) | 可折叠家具和可用于该家具的支撑架 | |
CA2036219A1 (fr) | Raccord a multiple armatures suspendues | |
WO2007025880A3 (fr) | Derives de pyrazolone | |
WO2000005223A3 (fr) | Composes chimiques | |
PL1703034T3 (pl) | System podwieszania sufitu | |
JP2005511826A5 (fr) | ||
ATE367081T1 (de) | Kreiselschwader | |
EE9800022A (et) | Karbapeneemühend, selle stabiliseerimismeetod ja stabiliseeritud vorm ning farmatseutiline kompositsioon | |
IS2839B (is) | 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-(1,5-A-)-1,3,5 triazine, handhverfur þess og lyfjafræðilega ásættanleg sölt sem tenglar við viðtaka fyrir "corticotropin releasing factor" | |
EP1258473A4 (fr) | Derives d'acide benzoique, procede de production desdits derives, et medicament contenant ces derives comme principe actif | |
CA2130664A1 (fr) | Agents antiparasitaires | |
AU2001231997A1 (en) | Interlock mechanisms | |
WO1999026942A8 (fr) | 5-(2-imidazolinylamino)-benzimidazole, derives et procedes de preparation et d'utilisation de ces derniers en tant qu'agonistes du recepteur alpha-adrenergique ayant une meilleure stabilite metabolique | |
WO2009054312A1 (fr) | Polyamide soluble à modifié par carbodiimide, son procédé de production, et solution à base de polyamide soluble à modifié par carbodiimide | |
JP2002542378A5 (fr) | ||
EP2033637A4 (fr) | Agent thérapeutique ou prophylactique pour la leucémie | |
CN105857365B (zh) | 一种玻璃幕墙运输小车 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |